Guidance for 2026 revenue was made explicit at $10 million, with commercialization now targeted for late 2026. The previous quarter did not provide specific 2026 revenue guidance.

Peetz announced 2026 net product sales guidance of $630 million to $650 million. He emphasized pipeline progress, noting the approval of CTEXLI for CTX, a tablet formulation of LIVMARLI, and ...

The exercised warrants were issued in connection with the Company's February 2024 financing and carried an exercise price of $0.20 per common share. The Company further announces that the remaining $0 ...

NFL.com's Matt Okada takes a historic deep dive into the 40-yard dash and lays out what to expect at the 2026 NFL Scouting ...

So you've decided to become a leaker. Be it government corruption, corporate malfeasance, evidence of Russian hacking, or just some garden-variety, messed up shit someone wants to stay under wraps—a ...

On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and ...

Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a global leader in epigenetics, today reported financial results for the twelve months ended ...

On track for INLIGHT clinical data update in 1Q 2026; fat loss similar to GLP-1 observed at three months and expected to continue over time and with higher doses of WVE-007 (INHBE GalNAc-siRNA), while ...

Scorpio Gold Corp. (TSXV: SGN) (OTCQB: SRCRF) (FSE: RY9) ("Scorpio Gold", or the "Company") is pleased to announce that, over the ...